EA8143: A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Recruiting
99 years or below
All
Phase
3
99999 participants needed
1 Location
Brief description of study
Request for collaborative review: CIRB serving as IRB of record.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
09 Apr 2021.
Study ID: 826834